Transcription factor decoys for the prevention of vein bypass graft failure

American Journal of Cardiovascular Drugs

Volumn 3, Issue 2, 2003, Pages 79-85

  Mann, Michael J ^a   Conte, Michael S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOUBLE STRANDED DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; OLIGOMER; PLATELET DERIVED GROWTH FACTOR; RNA; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA1; VIRUS VECTOR;

ANIMAL MODEL; ARTICLE; BLOOD VESSEL TRANSPLANTATION; CELL CYCLE; CELL PROLIFERATION; CLINICAL STUDY; CLINICAL TRIAL; COMPETITIVE INHIBITION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; FEASIBILITY STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC MANIPULATION; GRAFT FAILURE; HUMAN; HYPERPLASIA; INCUBATION TIME; INTIMA; LEG ARTERY; MORBIDITY; MORTALITY; MULTICENTER STUDY; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RABBIT; RANDOMIZATION; SAFETY; SMOOTH MUSCLE FIBER; TARGET ORGAN; VEIN GRAFT; VEIN WALL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; BLOOD VESSELS; CORONARY ARTERY BYPASS; CORONARY DISEASE; GENE THERAPY; GRAFT SURVIVAL; HUMANS; MOLECULAR MIMICRY; TISSUE ENGINEERING; TRANSCRIPTION FACTORS; VEINS;

EID: 0038278620     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303020-00001     Document Type: Article

References (34)

1. Conte MS. The ideal small arterial substitute: a search for the Holy Grail? FASEB J 1998; 12: 43-5
2. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia. J Vasc Surg 1991; 13: 885-90
3. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg 1987; 5: 126-36
4. Tanaka H, Sukhova GK, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993; 88: 1788-803
5. Cox JL, Chaisson DA, Gotleib AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis. Prog Cardiovasc Dis 1991; 34: 45-68
6. Ku DD, Caulfield JB, Kirklin JK. Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation 1991; 83: 402-11
7. Colman A. Antisense strategies in cell and developmental biology. J Cell Sci 1990; 97: 399-409
8. Zaug A, Been M, Cech T. The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature 1986; 324: 429-33
9. Bielinska A, Schivdasani RA, Zhang L, et al. Regulation of gene expression with double-stranded phosphothioate oligonucleotides. Science 1990; 250: 997-1000
10. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating -cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A 1993; 90: 8474-8
11. Simons M, Edelman ER, DeKeyser JL, et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70
12. Francis SE, Hunter S, Holt CM, et al. Release of platelet-ved growth factor activity from pig venous arterial grafts. J Thorac Cardiovasc Surg 1994; 108: 540-8
13. Hoch JR, Stark VK, Turnipseed WD. The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. J Vasc Surg 1995; 22: 51-8
14. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998; 98: 82-9
15. Mann MJ, Gibbons GH, Kernoff, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci U S A 1995; 92: 4502-6
16. Gaubatz S, Wood JG, Livingston DM. Unusual proliferation arrest and transcriptional control properties of a newly discovered E2F family member, E2F-6. Proc Natl Acad Sci U S A 1998; 95: 9190-5
17. Morishita R, Gibbons GH, Horiuchi M, et al. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995; 92: 5855-9
18. Ehsan A, Mann MJ, Dell'Acqua G, et al. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 121: 714-22
19. Mann MJ, Gibbons GH, Tsao PS, et al. Cell cycle inhibition preserves endothelial function in genetically engineered vein grafts. J Clin Invest 1997; 99: 1295-301
20. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor-kB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-9
21. Kume M, Komori K, Matsumoto T, et al. Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation 2002; 105: 1226-32
22. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex vivo gene therapy for human bypass vein grafts: The PREVENT single centre randomised clinical trial. Lancet 1999; 354: 1493-8
23. Mann MJ, Gibbons GH, Poston R, et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A 1999; 96: 6411-6
24. Grube E, Felderhoff T, Fitzgerald PJ, et al. Phase II Trial of the E2F Decoy in Coronary Bypass Grafting. Oral presentation in the Late Breaking Clinical Trials session of the Annual Scientific Sessions of the American Heart Association; Nov. 11-14, 2001, Anaheim, CA
25. Cooper Jr JA, Parks JM, Carcelen R, et al. Attenuation of interleukin-8 production by inhibiting nuclear factor-κB translocation using decoy oligonucleotides. Biochem Pharmacol 2000; 59: 605-13
26. Morishita R, Gibbons GH, Ellison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994; 94: 978-84
27. Dzau VJ, Mann MJ, Morishita R, et al. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci U S A. 1996; 93: 11421-5
28. Poston RS, Mann MJ, Hoyt EG, et al. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method. Transplantation 1999; 68: 825-32
29. von der Leyen HE, Braun-Dullaeus R, Mann MJ, et al. A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer. Hum Gene Ther 1999; 10: 2355-64
30. Iwase R, Namba M, Yamaoka T, Murakami A. Gene regulation by decoy approach (I): synthesis and properties of photo-crosslinked oligonucleotides. Nucleic Acids Symp Ser 1997: 37; 203-4
31. Amoah-Apraku B, Fang MZ, Guzman NJ. A non-nucleotide-bridged DNA decoy inhibits renal epithelial nitric oxide synthase expression. Kidney Int 2000; 57: 83-91
32. Lebruska LL, Maher III LJ. Selection and characterization of an RNA decoy for transcription factor NF-κ B. Biochemistry 1999; 38: 3168-74
33. Hosoya T, Takeuchi H, Kanesaka Y, et al. Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett 1999; 461: 136-40
34. Ehsan A, Mann MJ; Dell'Acqua G, Tamura K, et al. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation 2002; 105 (14): 1686-92